Taysha Gene Therapies, Inc. TSHA · Stock Open Taysha Gene Therapies, Inc. in new tab
Taysha Gene Therapies, Inc. Analysis (TSHA)
Is Taysha Gene Therapies, Inc. a good investment? Taysha Gene Therapies, Inc. (TSHA) is currently trading at 6.21 USD. Market analysts have a consensus price target of 13.25 USD. This suggests a potential upside from current levels.
Earnings Schedule: Taysha Gene Therapies, Inc. is expected to release its next earnings report on Nov. 3, 2026. The market consensus estimate for Forward EPS is -0.47.
Investor FAQ
Does Taysha Gene Therapies, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 3, 2026. The company currently has a trailing EPS of -0.41.
Company Profile
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Community Discussion